Literature DB >> 2794225

Hyperresponsibility to exogeneous interleukin 4 in atopic dermatitis.

M Furue, F Ogata, M Ootsuki, Y Ishibashi.   

Abstract

Many humoral and cellular immunological abnormalities have been reported in atopic dermatitis (AD). Since interleukin 4 (IL-4) enhances IgE production and IgE-Fc receptor expression by B cells as well as [3H]-TdR incorporation by T cells, we hypothesized that IL-4 may play an important role in the regulation of the immune response in AD. We examined [3H]-TdR incorporation by peripheral blood lymphocytes from AD patients or from non-AD controls in the presence or absence of IL-4 or interleukin 2 (IL-2). We found that IL-4/IL-2 responsiveness was significantly higher in AD than controls, although the IgE levels did not seem to be correlated with IL-4/IL-2 responsiveness. It is possible that most humoral and cellular immunological abnormalities of AD may be due to this hyperresponsibility to IL-4.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2794225     DOI: 10.1111/j.1346-8138.1989.tb01258.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  3 in total

Review 1.  Interactions between host factors and the skin microbiome.

Authors:  Adam SanMiguel; Elizabeth A Grice
Journal:  Cell Mol Life Sci       Date:  2014-12-30       Impact factor: 9.261

2.  Fc epsilon receptor II/CD23+ lymphocytes in atopic dermatitis. III. Aberrant control in the in vitro expression of Fc epsilon RII/CD23 on peripheral blood T cells in atopic dermatitis.

Authors:  T Sakamoto; F Nakayama; T Tamamori; M Takigawa
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

3.  Taeumjowi-tang, a Traditional Korean Sasang Remedy, Improves Obesity-Atopic Dermatitis Comorbidity by Regulating Hypoxia-Inducible Factor 1 Alpha.

Authors:  Jinbong Park; Dong-Hyun Youn; JongWook Kang; Kwang Seok Ahn; Hyun Jeong Kwak; Jae-Young Um
Journal:  Front Pharmacol       Date:  2019-12-20       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.